The UK government's ban on prescribing puberty blockers for adolescents experiencing gender dysphoria has ignited heated debate, dividing public opinion on the rights and well-being of transgender youth.
The contentious measure, endorsed by both major political parties, follows recommendations from the Cass Review and is set to have far-reaching implications for healthcare in England, Scotland, and beyond.
